{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T11:10:41Z","timestamp":1767006641932,"version":"3.44.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"am","delay-in-days":405,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.therap.2023.01.004","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T22:08:57Z","timestamp":1674166137000},"page":"523-529","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacovigilance follow-up of patients in the context of the COVID-19 pandemic"],"prefix":"10.1016","volume":"78","author":[{"given":"Aur\u00e9lie","family":"Grandvuillemin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanny","family":"Rocher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie Blanche","family":"Valnet-Rabier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milou-Daniel","family":"Drici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Dautriche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2023.01.004_bib0105","unstructured":"HCSP. Avis relatif \u00e0 la prise en charge des cas confirm\u00e9s d\u2019infection au virus SARS-CoV2. 5 mars 2020. https:\/\/www.hcsp.fr\/explore.cgi\/avisrapportsdomaine?clefr=771.[Accessed 9 January 2023]."},{"key":"10.1016\/j.therap.2023.01.004_bib0110","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s40264-020-01034-y","article-title":"French pharmacovigilance Network. French pharmacovigilance Network. French pharmacovigilance public system and COVID-19 pandemic","volume":"44","author":"Grandvuillemin","year":"2021","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2023.01.004_bib0115","unstructured":"ANSM. Suivi des effets ind\u00e9sirables des m\u00e9dicaments utilis\u00e9s dans la prise en charge du COVID-19. 2022. http:\/\/ansm.sante.fr\/dossiers-thematiques\/covid-19-dispositif-renforce-de-pharmacovigilance-et-daddictovigilance. [Accessed 9 January 2023]."},{"key":"10.1016\/j.therap.2023.01.004_bib0120","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.therap.2016.02.010","article-title":"Causality assessment in pharmacovigilance: the French method and its successive updates","volume":"71","author":"Miremont-Salam\u00e9","year":"2016","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2023.01.004_bib0125","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.therap.2022.03.001","article-title":"Pharmacovigilance and drug safety: fair prescribing and clinical research","volume":"77","author":"Montastruc","year":"2022","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2023.01.004_bib0130","unstructured":"European medicines agency. ICH Topic E 2 A: Clinical Safety Data Management: definitions and standards for expedited reporting, June 1995, Guideline no. CPMP\/ICH\/377\/95. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-15.pdf.[Accessed 9 January 2023 (10 pp.)]."},{"issue":"Suppl. S1","key":"10.1016\/j.therap.2023.01.004_bib0135","first-page":"23","article-title":"a feasibility study of an electronic system for the reporting of drug misuse in primary care. PM1-034","volume":"33","author":"Valnet Rabier","year":"2019","journal-title":"Fund Clin Pharmacol"},{"key":"10.1016\/j.therap.2023.01.004_bib0140","unstructured":"HCSP. Rapport relatif \u00e0 l\u2019actualisation de la prise en charge des patients atteints de COVID-19. 20 July 2020. https:\/\/www.hcsp.fr\/Explore.cgi\/Telecharger?NomFichier=hcspr20200723_corsarcovactdelapriencha.pdf.[Accessed 9 January 2023 (291 pp.)]."},{"key":"10.1016\/j.therap.2023.01.004_bib0145","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.therap.2020.05.011","article-title":"R\u00e9seau fran\u00e7ais des centres r\u00e9gionaux de pharmacovigilance. The French pharmacovigilance surveys: a French distinctiveness, a real input","volume":"76","author":"Abou Taam","year":"2021","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2023.01.004_bib0150","unstructured":"Sant\u00e9 publique France. 2022. https:\/\/www.santepubliquefrance.fr\/dossiers\/coronavirus-covid-19\/coronavirus-chiffres-cles-et-evolution-de-la-covid-19-en-france-et-dans-le-monde.[Accessed 9 9 January 2023]."},{"key":"10.1016\/j.therap.2023.01.004_bib0155","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.therap.2020.05.002","article-title":"R\u00e9seau fran\u00e7ais des centres de pharmacovigilance. Off-label use of hydroxychloroquine, azithromycin, lopinavir\/ritonavir and chloroquine in COVID-19: survey on cardiac adverse drug reactions by the French Network of pharmacovigilance centres","volume":"75","author":"G\u00e9rard","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2023.01.004_bib0160","unstructured":"ANSM. Plaquenil et Kaletra\u00a0: les traitements test\u00e9s pour soigner les patients COVID-19 ne doivent \u00eatre utilis\u00e9s qu\u2019\u00e0 l\u2019h\u00f4pital. Point d\u2019information. 30 March 2020. https:\/\/ansm.sante.fr\/actualites\/plaquenil-et-kaletra-les-traitements-testes-pour-soigner-les-patients-covid-19-ne-doivent-etre-utilises-qua-lhopital.[Accessed 9 January 2023]."},{"key":"10.1016\/j.therap.2023.01.004_bib0165","unstructured":"HCSP. COVID-19\u00a0: utilisation de l\u2019hydroxychloroquine. May 2020. https:\/\/www.hcsp.fr\/explore.cgi\/avisrapportsdomaine?clefr=837.[Accessed 9 January 2023]."},{"key":"10.1016\/j.therap.2023.01.004_bib0170","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.therap.2021.12.015","article-title":"R\u00e9seau fran\u00e7ais des Centres r\u00e9gionaux de pharmacovigilance. Comparative study of the adverse event profile of hydroxychloroquine before and during the Sars-CoV2 pandemic","volume":"77","author":"Lory","year":"2022","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2023.01.004_bib0175","unstructured":"Lory P., Combret S., Michot J., Veyrac G., Chouchana L., Grandvuillemin A. Safety profile of the lopinavir\/ritonavir combination before and during the SARS-CoV2 pandemic. Therapie 2022 Oct 31:S0040-5957(22)00235-9. doi: 10.1016\/j.therap.2022.10.066. Epub ahead of print.https:\/\/www.em-consulte.com\/article\/1554514\/safety-profile-of-the-lopinavirritonavir-combinati. [Accessed 9 January 2023]."},{"key":"10.1016\/j.therap.2023.01.004_bib0180","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.therap.2020.05.003","article-title":"French Society of pharmacology, therapeutics (SFPT). Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection","volume":"75","author":"Micallef","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2023.01.004_bib0185","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.therap.2020.07.008","article-title":"COVID-19 and NSAIDs: primum non nocere","volume":"75","author":"Micallef","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2023.01.004_bib0190","unstructured":"EPIPHARE. Usage des m\u00e9dicaments de ville en France durant l\u2019\u00e9pid\u00e9mie de la Covid-19 \u2013 point de situation apr\u00e8s les 8 semaines de confinement et une semaine de post-confinement. Rapport 3 du 9 juin 2020. 9 June 2020. https:\/\/ansm.sante.fr\/uploads\/2020\/10\/13\/20201013-epi-phare-rapport-covid-3-1usage-medic.pdf.[Accessed 9 January 2023 (312 pp.)]."},{"key":"10.1016\/j.therap.2023.01.004_bib0195","doi-asserted-by":"crossref","first-page":"E295","DOI":"10.1002\/ajh.25935","article-title":"Heparin induced thrombocytopenia antibodies in Covid-19","volume":"95","author":"Patell","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.therap.2023.01.004_bib0200","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.therap.2021.05.003","article-title":"French Network of pharmacovigilance centres. French organization for the pharmacovigilance of COVID-19 vaccines: a major challenge","volume":"76","author":"Lacroix","year":"2021","journal-title":"Therapie"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595723000215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595723000215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:56:16Z","timestamp":1758567376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595723000215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0040595723000215"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2023.01.004","relation":{},"ISSN":["0040-5957"],"issn-type":[{"type":"print","value":"0040-5957"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacovigilance follow-up of patients in the context of the COVID-19 pandemic","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2023.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}